1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: None of our directors or officers adopted , modified, or terminated a Rule 10b5–1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended September 30, 2024, as such terms are defined under Item 408(a) of Regulation S-K.
+Added: The following officers and directors of the Company adopted trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
+Added: The plans became effective during the three months ended March 31, 2025.
+Added: The material items of the trading plan are set forth in the table below:
+Added: Name of the Director or Officer Title of the Director or Officer Date of Adoption Duration of the Trading Plan Maximum Dollar Amount to be Used in the Purchase of the Securities
+Added: Kazimi Chief Executive Officer November 14, 2024 March 3, 2025 - December 31, 2025
+Added: Krogulski Director November 14, 2024 March 3, 2025 - December 31, 2025
+Added: Jones Director November 14, 2024 March 3, 2025 - December 31, 2025
+Added: Young Director November 14, 2024 March 3, 2025 - December 31, 2025
+Added: 10.1# Employment Agreement dated March 4, 2025, effective as of January 1, 2025, by and between A.J.
+Added: Kazimi and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K (File No.
+Added: 001-33637) as filed with the SEC on March 7, 2025.
+Added: 10.2# Employment Agreement dated March 4, 2025, effective as of January 1, 2025, by and between Jim Herman and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.12 of the Company’s Annual Report on Form 10-K (File No.
+Added: 001-33637) as filed with the SEC on March 7, 2025.
+Added: 10.3# Employment Agreement dated March 4, 2025, effective as of January 1, 2025, by and between Todd Anthony and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.13 of the Company’s Annual Report on Form 10-K (File No.
+Added: 001-33637) as filed with the SEC on March 7, 2025.
+Added: 10.4# Employment Agreement dated March 4, 2025, effective as of January 1, 2025, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.14 of the Company’s Annual Report on Form 10-K (File No.
+Added: 001-33637) as filed with the SEC on March 7, 2025.
+Added: 10.5# Employment Agreement dated March 4, 2025, effective as of January 1, 2025, by and between John M.
+Added: Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.15 of the Company’s Annual Report on Form 10-K (File No.
+Added: 001-33637) as filed with the SEC on March 7, 2025.
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
** Furnished herewith.
+Added: # Indicates a management contract or compensatory plan
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Cumberland Pharmaceuticals Inc.
−Removed: November 8, 2024 By:
+Added: May 9, 2025 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.